Gordon J Freeman

59PUBLICATIONS

379CO-AUTHORS

Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Innate immunity

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (59)

Sort by Publication Date:

|Jun 17, 2026

IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma.

|Jun 15, 2026

Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T-cell responses during chronic viral infection.

|May 18, 2026

Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.

|May 04, 2026

Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer.

|Apr 08, 2026

Selective depletion of virus-specific CD8 T cells from the liver after PD-1 therapy with Fc-intact antibody during chronic infection.

Masao Hashimoto, Tahseen H Nasti, Hyun-Tak Jin

|Mar 26, 2026

Exposed phosphatidylserine is an inhibitory molecule in T cell exhaustion.

Christopher B Medina, Ewelina Sobierajska, Minghao Gong

Pageof 10

Frequent Collaborators

12 joint publications

Arlene H Sharpe

Wenyi Wei

Jinfang Zhang

Catherine J Wu

Rafi Ahmed

Toni K Choueiri

Sabina Signoretti

Kathleen M Mahoney

David A Braun

David F McDermott

Frequent Collaborators

12 joint publications

Arlene H Sharpe

7 joint publications

Wenyi Wei

6 joint publications

Jinfang Zhang

6 joint publications

Catherine J Wu